These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 34805582)

  • 1. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.
    Satiya J; Snyder HS; Singh SP; Satapathy SK
    Transl Gastroenterol Hepatol; 2021; 6():60. PubMed ID: 34805582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis.
    Ganguli S; DeLeeuw P; Satapathy SK
    Hepat Med; 2019; 11():159-178. PubMed ID: 31814783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis.
    Sinakos E; Liava C; Loomba R
    Ann Gastroenterol; 2022; 35(3):213-225. PubMed ID: 35599922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Khan FZ; Perumpail RB; Wong RJ; Ahmed A
    World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
    Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
    An J; Sohn JH
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.
    Yoon IC; Eun JR
    Yeungnam Univ J Med; 2019 May; 36(2):67-77. PubMed ID: 31620616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
    Yang YY; Xie L; Zhang NP; Zhou D; Liu TT; Wu J
    Acta Pharmacol Sin; 2022 May; 43(5):1180-1190. PubMed ID: 35190696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
    Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
    Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
    Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.